Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea

Won, Hyeran; Kim, Ahra; Yoo, Jung-Sik; Chung, Gyung Tae; Kang, Hae Ji; Kim, Su Jin; Kim, Sung Soon; Lee, June-Woo

doi:10.1016/j.vaccine.2021.01.039

Cited by 13 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the remarkable public health success of the mumps vaccine, evidence of virus escape from vaccine-induce immunity is piling up [19][20][21][22][23][24][25][26][27], suggesting that a new vaccine with better-matched epitopes or a different strategy might be needed soon. Although there were numerous trials to make a universal influenza vaccine (reviewed in Reference [28]), most influenza vaccines approved today still contain the inactivated virus, its subunits or purified hemagglutinin and neuraminidase of four influenza viruses (subtypes H1N1 and H3N2 of type A and lineages Victoria and Yamagata of type B) [29].…”

Section: Introductionmentioning

confidence: 99%

“…Meanwhile, pathogen evolution has continued generating new variants under the influence of vaccine-driven evolutionary pressure, and while measles and rubella vaccines seem to resist the evolutionary pressure, the mumps vaccine shows signs of failure. Despite the remarkable public health success of the mumps vaccine, evidence of virus escape from vaccine-induce immunity is piling up [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ], suggesting that a new vaccine with better-matched epitopes or a different strategy might be needed soon. Although there were numerous trials to make a universal influenza vaccine (reviewed in Reference [ 28 ]), most influenza vaccines approved today still contain the inactivated virus, its subunits or purified hemagglutinin and neuraminidase of four influenza viruses (subtypes H1N1 and H3N2 of type A and lineages Victoria and Yamagata of type B) [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

Šantak

Matić

2022

Viruses

View full text Add to dashboard Cite

Negative-stranded RNA viruses (NSVs) are important human pathogens, including emerging and reemerging viruses that cause respiratory, hemorrhagic and other severe illnesses. Vaccine design traditionally relies on the viral surface glycoproteins. However, surface glycoproteins rarely elicit effective long-term immunity due to high variability. Therefore, an alternative approach is to include conserved structural proteins such as nucleoprotein (NP). NP is engaged in myriad processes in the viral life cycle: coating and protection of viral RNA, regulation of transcription/replication processes and induction of immunosuppression of the host. A broad heterosubtypic T-cellular protection was ascribed very early to this protein. In contrast, the understanding of the humoral immunity to NP is very limited in spite of the high titer of non-neutralizing NP-specific antibodies raised upon natural infection or immunization. In this review, the data with important implications for the understanding of the role of NP in the immune response to human NSVs are revisited. Major implications of the elicited T-cell immune responses to NP are evaluated, and the possible multiple mechanisms of the neglected humoral response to NP are discussed. The intention of this review is to remind that NP is a very promising target for the development of future vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

Šantak

Matić

2022

Viruses

View full text Add to dashboard Cite

show abstract

“…They did identify the following amino acid variants between the vaccine genotypes and circulating strains: I279T, I287V, L336S, and E356D, in known neutralizing epitope sites. They also identified SNVs in new predicted epitopes/ vaccine escapes sites: N121S, R122K, N123K/E and Y442S [7].…”

Section: Other Hn Snvsmentioning

confidence: 96%

“…The more recent outbreaks have shown a change in demographic: mumps is no longer a disease of young children, but instead, cases are occurring mainly in young adults [1][2][3][4][5]. What is driving this re-emergence is unknown, but it is likely due to waning vaccine immunity or a lack of cross-reactivity between the circulating strains and the vaccine strain [6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Mumps Virus Glycoproteins: A Review

Frost

Shaikh

Severini

2022

Viruses

View full text Add to dashboard Cite

The resurgence of mumps in vaccinated adult populations has raised concerns about possible waning vaccine immunity or a potential lack of protection to the circulating strain. A number of individual studies have investigated if there are amino acid variations between the circulating wild-type strains and vaccine strains. In these studies, the HN and F mumps surface glycoproteins have been of interest, because of their role in viral infection, and because the HN protein is the target of neutralizing antibodies. Here, we summarize the single nucleotide variants and their potential effect that have been identified between mumps genotypes in the HN and F proteins.

show abstract

“…Despite the remarkable public health success of the mumps vaccine, evidence of virus escape from vaccine-induced immunity causing mumps resurgence is piling up. Vanning immunity, lack of natural boost, and a reduced capacity of vaccine-induced neutralizing antibodies to cross-neutralize circulating strains have been suggested as factors facilitating mumps virus to escape from vaccine-induced immunity (Santak et al 2006;Ivancic-Jelecki et al 2008;Cortese et al 2011;Smits et al 2013;Šantak et al 2013;Šantak et al 2015a, b;May et al 2018;Ramanathan et al 2018;Marshall and Plotkin 2019;Vermeire et al 2019;Connell et al 2020;Won et al 2021) suggesting a new vaccine with better-matched epitopes will be needed soon. Hence, novel technologies for the development and production of vaccines are needed to effectively prevent and control infectious diseases in humans.…”

Section: Introductionmentioning

confidence: 99%

Current view on novel vaccine technologies to combat human infectious diseases

Matić

Šantak

2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1-3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. Key points• Vaccines of the new generation follow the minimalist strategy.• Some infectious diseases remain a challenge for the vaccine development.• The number of new vaccine candidates in the late phase clinical trials remains low.

show abstract

Cross-neutralization between vaccine and circulating wild-type mumps viruses in Korea

Cited by 13 publications

References 30 publications

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

Exploring the Mumps Virus Glycoproteins: A Review

Current view on novel vaccine technologies to combat human infectious diseases

Contact Info

Product

Resources

About